Skip to content

Clinical trial of Hair care supplements

A parallel arm clinical trial to validate safety and efficacy of Hair care product range (LS/HC/002) in adult males. - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048420
Enrollment
120
Registered
2022-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: LS/HC/OR/002: 1-2 capsules twice daily orally for 90 days Intervention2: LS/HC/TP/002: Apply sufficient amount of serum/ elixir to roots and entire length of hair daily for 90 days Inte

Sponsors

Life Synergy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male subjects in general good health, subjects in the age group 18-60 years, subjects willing to to give written informed consent and agree to come for a regular follow up visit, subjects not participated in a similar investigations in the past two weeks,subjects complaining of hair fall and damage, subjects who are not on crash dieting, subjects who agree to not to change the brand of currently used hair color, dye, treatment etc., if during the study term,subjects willing to refrain from any type of hair treatment like head massage, oil application, perming, etc. during the study duration, subjects with at least of two of following complaints- hair loss, dry damaged hair, brittle and thin hair, premature greying of hair, scalp related complaints like itching, dandruff or irritation

Exclusion criteria

Exclusion criteria: Subjects who are undergoing hair growth treatment within 3 months before screening into the study. Subjects having any active scalp disease which may interfere in the study. Subjects on treatment for active acne Subjects with history or active phase of malignancy and chemotherapy therefore. Subjects who have history of alcoholism and/ or psychiatric disorder including trichotillomania. Subjects who have had hair transplant. Subjects who take pharmaceutical product which cause hirsutism. Subjects on oral hair growth medications which will compromise the study. Chronic illness which may influence the study. Subjects participating in other similar cosmetic or therapeutic trial within last two weeks Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anaemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.

Design outcomes

Primary

MeasureTime frame
Changes in shredded hair strands in 60 second Hair comb test Changes in number of shredded hairs in Hair wash test Assessment by photo trichogram- -% Anagen and telogen Hair -Hair density and thickness -Terminal and vellus hair density -Hair growth rate (mm/day) Skin health assessment by CLBT scoreTimepoint: From baseline to day 90

Secondary

MeasureTime frame
To assess nail growth and satisfaction scale on nail health To assess improvement in the â??Hair Quality Assessment Questionnaireâ?? from baseline to End of the study. (Brittleness, thinning, dryness and damaged hair, luster, roughness, fizziness) To assess VAS- Visual analog scale scalp related complaints like itching, dandruff or irritation (Scalp health) tolerability including the ocular irritant potential and non-irritant potential on skinTimepoint: From baseline to day 90

Countries

India

Contacts

Public ContactMs Vaishnavi Padar

Life Synergy

vaishnavi.mprexhc@gmail.com9834585994

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026